Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, John Kent, NewTrader2017
Search This Board: 
Last Post: 1/20/2018 9:27:46 PM - Followers: 150 - Board type: Free - Posts Today: 24
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Innovus Pharma Announces Official Launch of its Amazon, Walmart, eBay and Wish On-Line Stores with a Combined 116 Product SKUs 01/18/2018 09:30:00 AM
INNV News: Current Report Filing (8-k) 01/08/2018 06:08:26 AM
INNV News: Quarterly Report (10-q) 11/14/2017 04:41:42 PM
INNV News: Current Report Filing (8-k) 11/14/2017 04:24:20 PM
INNV News: Current Report Filing (8-k) 11/14/2017 06:13:49 AM
#13070  Sticky Note Innovus Pharma Announces U.S. Food and Drug Administration kkpennies 01/11/18 10:21:10 AM
#12430  Sticky Note !!! $INNV Investor Starter Guide !!!! John Kent 11/20/17 10:31:19 AM
#11803  Sticky Note $19B market. I think I'd be loading up BooDog 10/03/17 06:04:18 AM
#13221   TF and Honey.. Still waiting on your responses Clev3land 01/20/18 09:27:46 PM
#13219   I'm busy watching college basketball like most normal Batermere 01/20/18 08:50:30 PM
#13218   Doc: Show me a photo of something INNV twistedfreak 01/20/18 07:32:11 PM
#13217   Yes. In many stores with many products in Batermere 01/20/18 05:28:06 PM
#13216   Just to be clear about what will be Destroyer67 01/20/18 05:16:25 PM
#13215   bt2: I think we are GOLDEN here now. Batermere 01/20/18 12:25:25 PM
#13214   agree with you on this one Bat, look biotech2 01/20/18 11:39:23 AM
#13213   I get your point, twisted. Yes, it still Batermere 01/20/18 10:40:29 AM
#13212   I'm just curious TF and Honey do you Clev3land 01/20/18 10:40:03 AM
#13211   That's such an OTC thing to say, Doc. twistedfreak 01/20/18 10:29:15 AM
#13210   bt2: Being obsessed with guidance for 2017 is Batermere 01/20/18 10:05:45 AM
#13209   I'm not against any of your concerns Honey Clev3land 01/20/18 10:04:27 AM
#13208   In a way I almost hope they don't Clev3land 01/20/18 09:58:01 AM
#13207   we'll do...this gets crushed if 10M+ doesn't happen Honeycomb777 01/20/18 09:40:24 AM
#13206   agree, a lot of investors are looking at biotech2 01/20/18 09:20:15 AM
#13205   Careful with the facts, Honey. They are not twistedfreak 01/20/18 09:10:45 AM
#13204   People don't even know what Da gave up Honeycomb777 01/20/18 08:58:24 AM
#13203   Thank you, by the way, I'm not the florida investor 01/20/18 08:43:25 AM
#13202   FYI: .60-$1 may be on the low side Batermere 01/20/18 08:27:25 AM
#13201   100% with you Batermere. The stream of revenue florida investor 01/20/18 08:15:43 AM
#13200   Yeah, REALLY twisted. IF INNV misses it, it Batermere 01/20/18 07:49:03 AM
#13199   Yeah Honey, the market doesn't care about missing twistedfreak 01/20/18 07:26:22 AM
#13198   This will be an excellent year for INNV. SamuelPro 01/20/18 01:15:45 AM
#13197   Nobody cares about hitting the $10 million mark Batermere 01/19/18 10:00:31 PM
#13196   Need to breach $10M for 2017 revs or Honeycomb777 01/19/18 09:25:44 PM
#13195   Lol. In a month people will be begging Clev3land 01/19/18 09:18:50 PM
#13192   What's the gig honey. Right now us the Clev3land 01/19/18 07:23:24 PM
#13190   Great week! all of my innovus shares are snupoled 01/19/18 05:21:56 PM
#13189   .18 was it for this round of the twistedfreak 01/19/18 05:20:08 PM
#13188   Right, the news was paved the way for SamuelPro 01/19/18 04:38:27 PM
#13187   Doing the same! SamuelPro 01/19/18 04:34:41 PM
#13186   AWESOME WEEK INNV! So flipping happy I bought Clev3land 01/19/18 04:17:21 PM
#13185   NICE GAINS this week for INNV !!!!! biotech2 01/19/18 03:23:04 PM
#13184   Don't need one, not for a while. $INNV BooDog 01/19/18 02:32:13 PM
#13183   pray for no PR after close..... no. whammy jbdiver 01/19/18 02:20:44 PM
#13182   Yeah, one in particular who boasted he owned Batermere 01/19/18 01:51:33 PM
#13181   Won't take much now to cut into the BooDog 01/19/18 01:42:42 PM
#13179   Looking good for 2018. Green is good! $INNV BooDog 01/19/18 01:32:59 PM
#13178   U funny - this tanks when his 15M Honeycomb777 01/19/18 01:27:22 PM
#13177   New to purchasing of Innovus Pharmaceuticals. Great news harris08 01/19/18 10:05:13 AM
#13176   it could be a chunk of my retirement funds biotech2 01/19/18 09:20:40 AM
#13175   I'm getting there. 500K would be nice. Ching Ching. Batermere 01/19/18 09:18:59 AM
#13174   I would add if I had any more biotech2 01/19/18 09:10:05 AM
#13170   Innovus Pharma Announces Official Launch of its Amazon, florida investor 01/19/18 06:30:37 AM
#13169   I can definetely see this company above .50 florida investor 01/19/18 06:03:16 AM
#13168   I sense that Honey and TF are frustrated Clev3land 01/19/18 05:06:25 AM
#13167   #INNV: Well then under valued now...-:} captainscotty 01/18/18 07:44:57 PM
#13166   Value is adding up. Today was huge as SamuelPro 01/18/18 06:49:30 PM
#13164   Excellent work John! Love to see $INNV added BooDog 01/18/18 05:22:08 PM
#13163   John, I never said that. I said the twistedfreak 01/18/18 04:45:17 PM